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MULTIPLE INDIVIDUAL AND CROSS-SPECIFIC IDIOTYPES ON
13 LEVAN-BINDING MYELOMA PROTEINS OF BALB/c MICE
By ROSE LIEBERMAN, MICHAEL POTTER, WILLIAM HUMPHREY, JR., ELIZABETH B.
MUSHINSKI, AND MARK VRANA
(From the National Institute of Allergy and Infectious Diseases and the National
CancerInstitute, NationalInstitutes ofHealth, Bethesda, Maryland 20014)
Studies of immunoglobulin V-region antigenic determinants (idiotypes) are
important in understanding the genetics and evolution of antibodies and the
generation of antibody diversity. The finding of homogeneous immunoglobulins
(myeloma proteins, Waldenstrom macroglobulins M-components) that bind the
same hapten or antigen has added immeasurably to these studies. The best
studied systems to date are the human IgM proteins that bind -y-globulin (1-3),
and the IgM cold agglutinins (4-6) and the mouse phosphorylcholine (7-10),
al,2 and al,6 dextran (11-16), levan-(11, 14) and galactan-(17) binding
myeloma proteins. Generally in these studies two typesofantigenic determinants
or idiotypes have been found within a functional group, individual antigenic
determinants (IdI) ' or idiotypic determinants specific for the homogeneous
immunoglobulin within the group and cross-specific (IdX) or common idiotypic
determinants which are shared among some of the functionally related proteins
within a group but which are not or very rarely found among unrelated
immunoglobulins. Structurally IdI and IdX are both located on the domains of
the immunoglobulin molecule formed by the V, and VH polypeptides. Some
idiotypic determinants are contiguous to or directly involve peptide segments or
amino acids in the binding sites and the interaction of hapten with the
homogeneous immunoglobulin may block the anti-idiotypic antibody (9, 14, 18).
Other V-region idiotypic antigens are genetic in that within the species, they may
be derived from polymorphic genes (8, 12, 19-21) .
In this study we have examined the idiotypic determinants ofthe largest group
of specific antigen-binding myeloma proteins found thus far in the mouse,
namely, the levan-binding proteins. These proteins have been shown to possess
two types ofbinding specificity, one groupof 11 proteins binds fructosans suchas
inulin which are linear polysaccharides with ,82-1 linkages and bacterial
(Aerobacter) levan; the second group of two proteins binds determinants on
bacterial levans which are probably fructosans with a2,6 linkages (11). This
latter point has not yet been clearly established since appropriate oligosaccharide
inhibitors are not yet available.
'Abbreviations used in this paper: HA, hemagglutination; HI, hemagglutination inhibition ; IdI,
individual antigenic determinants; IdX, cross-specific determinants; LBMP, levan-binding myeloma
proteins.
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The idiotypic sera prepared to levan-binding myeloma proteins (LBMP) were
unusual in that they identified a large number of 1dX in addition to the usual
individual idiotypes. The IdX of LBMP indicated the close relationship of this
family of proteins. We were able to show also that some IdI and IdX of LBMP
were closely related to the antigen-binding site.
Materials and Methods
MyelomaProteins.
￿
The 13 LBMP used in the study are listed in Table I. The tumors producing
theseproteins were all of BALB/c origin.The proteins were initially typedwith antiallotype antisera
TABLE I
Origin and Characteristics of Plasma Cell Tumors Producing Levan-Binding
Myeloma Proteins
In the paper the myeloma proteins will be designated by the first letter followed by the number, e.g.
ABPC48 = A48.
*Plasmacytoma (myeloma) wasinducedby i.p . injection of mineral oil (M), pristane (P) or Pristane
and Abelson virus (V).
$Agglutination of palmitoyl levan, or palmitoyl inulin-coated SRBC.
§ This paper.
and 11 proteins ABPC48, ABPC47, UPC61, W3082, MOPC702, EPC109, TEPC803, ABPC51,
ABPC4, AMPC1, and ABPC45 were of the IgA class and carried Cx determinants A"" """, one
(UPC10) was an IgG protein with CH determinants G1.6.7.° and one (J606) was an IgG3 protein.
ABPC4, ABPC47, ABPC48, UPC61, UPC10, TEPC803, EPC109, andAMPC1were precipitated from
ascitesor diluted serum at 4*C with 37-50% saturation with ammonium sulfate. Theprecipitate was
resolubilized in phosphate-buffered saline and then dialyzed against physiologic saline. In addition,
sera or ascitesfrom 106different BALB/c plasmacytomas notbindinglevan were also tested for levan
cross-specific idiotypic determinants. J606 andW3082 myelomaproteins were kindly supplied to us
by Dr. M. Weigert, Institute for Cancer Research, Philadelphia, Pa.
Anti-Idiotype Antisera. For the most part to successfully prepare anti-idiotype antiserum to
BALB/c myeloma proteins, the strain to be immunized hasto be of a different IgC allotype than the
BALBc and also possess the appropriate H-2-linked immune response (Ir) gene (22, 23). For these
reasons strain A/He which lacked I9CA'z, " of BALBc and possesses the appropriate Ir-la gene
whichcontrols the maximalimmune response to IgAmyeloma protein wasselected forimmunization
with ABPC4, ABPC47, ABPC48, UPC61, TEPC803, EPC109, AMPC1, and W3082 myeloma
Myeloma
Induction
method* Origin
Myeloma
protein
class
Bindingto
A.leuanicum
Levan$
Inulin
Ref.
J606 M Salk Inst. IgG, + + 11, 14, 27, 28
ABPC48 P +V NIH IgA + - §
ABPC47 P +V NIH IgA + + §
UPC61 M NIH IgA + + 11
W3082 M Salk Inst. IgA + + 11, 14,27, 28
MOPC702 M NIH IgA + + §
EPC109 M NIH IgA + + §
TEPC803 P NIH IgA + + §
ABPC51 P + V NIH IgA + + §
ABPC4 P + V NIH IgA + + §
UPC10 M NIH IgG2, +- - 11,14
AMPC1 M NIH IgA + + §
ABPC45 P + V NIH IgA + + §108
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proteins. Similarly B10.M mice which lacks IgCG', 6. 7, e of BALB/c and possesses Ir-1b were
immunized with UPC10 and SJL mice were immunized with J606 myeloma proteins. No allotypic
markers have thus far been identified for IgG3 in mice. All mice were immunized according to the
method previously described (23) . Antisera prepared with IgA myeloma proteins were made specific
for idiotype by the addition of 0.025 ml MOPC167 (3 mg/ml) to 0.1 ml of each antiserum to inhibit the
allotype. MOPC167 is aBALB/c IgA myeloma which shares the IgC allotypes butnotidiotype of the
IgA antilevan myeloma proteins. Similarly, B10.M anti-UPC10 antisera were made specific for the
idiotype by the addition of adj. PC5(IgG,a) myeloma protein; anti-J606 required no absorption.
Anti-Idiotype Antibody Assay. The hemagglutination (HA) and hemagglutination inhibition
(HI) methods previously described using chromic chloride treated SRBC coated with the specific
myeloma protein were employed (8) . The anti-idiotype specific antisera were first absorbed with an
appropriate non-LBMP and the HA titer of the antiserum, for each of the LBMP-SRBC systems was
determined. Specific IdI HA systems were then developed by further absorbing the antisera with an
appropriate cross reacting LBMP. Cross-specific HA systems were constructed by using an antiserum
prepared to one LBMP andSRBC-coupled with a cross-reacting LBMP. The HI method wasused to
determine if amyeloma protein shared idiotypic specificities with the myeloma protein coupled to the
SRBC . The HI titer of a given inhibitor was compared with the HI titer of protein coupled to the
SRBC . Inhibitors giving comparable titers were judged to be identical, those giving much less but
significant inhibition were arbitrarily judged to be partial determinants. At this time the system is
not yet quantitative because we do nothave a suitable immunoabsorbant andthe distinction between
partial and identical is tentative. In most instances approximately 1 mg/ml of the specific myeloma
protein inhibitor was used. However, ascites were used as inhibitors for A51, M702, and J606 and the
greatest dilution giving complete inhibition wasthen determined.
Antilevan and Anti-Inulin Activity of Myeloma Proteins. Levan was isolated from culture
supernates ofAerobacter levanicum ATCC 15552 grown in nutrient broth at 23°C supplemented with
5-10% sucrose. The culture supernates were brought to 80% saturation with ethanol, which
precipitated the levan. The levan was solubilized in H,0 and dialyzed extensively. Inulin was
obtained commercially from Nutritional Biochemicals Corp., Cleveland, Ohio. The palmitoyl
derivative of Aerobacter levanicum was prepared according to the method of Tsumita and Ohashi
(24); 10 mg of lyophilized levan was dissolved in 1 ml pyridine in a screw cap vial, heated in awater
bath, and 1 ul palmitoyl chloride added (Eastman Organic Chemicals, Rochester, N.Y.) . The
palmitoyl chloride was added quickly to avoid precipitation in the pipette by pyridine. For different
polysaccharides, the amount of palmitoyl chloride can be varied to produce optimal derivatives. The
mixture was then stirred at room temperature for 48-72 hr, precipitated in 80% saturated isopropyl
alcohol, and centrifuged. The precipitate was dissolved in 1 ml water, dialyzed, and coupled to
saline-washed SRBC . Occasionally the palmitoyl-levan adhered to the glass vial, and when this
occurred the precipitate was dissolved in water. Varying amounts of palmitoyl-levan ranging from
0.05 to 0.2 ml were added to 1 ml 2.5% SRBC. The coupling procedure wascarried out at 37'C for 1 hr.
Thesame procedure wasused for inulin except that inulin is relatively insoluble in pyridine. 20 mg
inulin was added to 1 ml pyridine, heated, the supernate decanted, and to this 20 dal palmitoyl
chloride was added. The oligosaccharide ,82-1 fructosan trisaccharide was prepared from Dahlia
Inulin by the method of Painter (25). The inulin hydrolysate was evaporated to a syrup that was
applied to 3-0 Whatman paper, and the oligosaccharides were separated chromatographically in a
butanol:pyridine:water (10:4:3) system for 100 h at room temperature. The oligosaccharides were
tentatively identified by their relative migration compared to fructose andsucrose . The trisaccharide
waseluted from the band that migrated just behind sucrose. The HI titer of fructosan trisaccharide
was determined for each IdI andIdX system. An 0.028 M solution of the trisaccharide was diluted in
the microtiter plates and to each dilution the myeloma protein-coated SRBC were added andallowed
to stand for 30 min at room temperature. Specific antiserum wasthen added andthe HI titer was read
at 3 and 24 h.
Results
Antisera Prepared to One Levan-Binding Myeloma Protein Usually Cross-
Reacts with Other Levan-Binding Myeloma Proteins. Idiotypic antisera pre-TABLE II
Hemagglutination Titers of Cross-Reacting Idiotypic Antibodies for Levan-Binding
Myeloma Proteins
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pared to 9 (except J606) of the 10 levan-binding myeloma proteins agglutinated
both SRBC coated with the immunizing myeloma protein and SRBC coated with
other LBMP (Table 1I). Some of the antisera agglutinated SRBC coated with the
other LBMP in roughly equal titers to the homologous protein, e.g., anti-W3082
and anti-E109 antisera.
In some instances much weaker HA titers were observed with the cross-react-
ing antibodies. This was particularly apparent when one compared the cross-
reacting titers with the titer obtained with the homologous proteins. Anti-A48
antiserum is a good example; anti-A48 reacted to A48 protein, with a log 2 titerof
17 ; to A47 a titer of 14 and E109, U61, W3082, Aml, A4 myeloma proteins titers
ranging from 9-12.
10559-10909 absorbed with M167 (IgA) to remove allotype specificities; 9305 absorbed with Adj.PC5
(IgG2a) to remove allotype specificities; 6470 prepared in SJL did not exhibit allotypic specificities.
* A = AIHe strain obtained from Delta Uphoff, NIH.
Preparation of Idiotypic Antiserum Specific for Individual Specificities on
each Myeloma Protein. Each of the 10 antisera prepared to different LBMP
could be made specific for the Idl determinant by absorption with theappropriate
cross-reacting myeloma protein (Table 111) . For example, absorption of anti-A48
antiserum with W3082 myeloma protein removed the cross-reactions with pro-
teins A4, A47, U61, W3082, E109, Aml, and T803 while practically having no
effect on the titer to A48 the homologous protein (Tables 11, 111). Even those
antisera showing very strong cross-reactions could be made Idl-specific by ab-
sorption with a strong cross-reacting myeloma protein. This is demonstrated
by the absorption of anti-U61 with W3082 protein which removed all the strong
cross-reactions to A4, W3082, E109, Aml, and T803 and the weaker reaction to
A48. In this instance however, the HA titer to U61 coated-SRBC was reduced
from 19 to 14 (log 2) after absorption. This was also true of anti-W3082 and anti-
HA titers (log 2)
SRBC coated with myeloma proteins
Antisera
A A A U W U J E Am T
4 47 48 61 3082 10 606 109 1 803
10559 A* anti-A48 12 14 17 10 12 0 0 9 12 10
10548 Aanti-A47 0 19 11 0 9 0 0 0 9 0
10544 Aanti-A4 17 7 5 13 14 0 0 14 12 13
10570 Aanti-U61 16 0 7 19 16 0 0 15 17 15
10789 Aanti-W3082 14 0 0 13 17 0 0 12 15 14
10898 Aanti-E109 13 0 0 12 14 0 0 14 10 11
10878 Aanti-Am1 10 8 8 10 12 0 0 0 17 11
10909 Aanti-T803 10 8 8 12 15 0 0 12 12 16
9305 1310.M anti-U10 6 4 5 4 4 13 0 0 0 0
6470 SJL anti-J606 0 0 0 0 0 0 0 0 0 0110
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TABLE III
Hemagglutination Titers of Individual Idiotypic Antibodies for Levan-Binding
Myeloma Proteins
10559-10909 absorbed with M167 (IgA) to remove allotypic specificities; 9305 absorbed with adj .PC5
(IgG2a) to remove allotypic specificities; 6470 prepared in SJLdid not exhibit allotypic specificities.
E109 sera which showed a reduction of titer to the homologous protein after
absorption. Anti-J606 antiserum did not require absorption and only identified
anIdI on J606.
Identification of Idiotypic IdX among LBMP.
￿
As indicated in Table II there
were many cross-reactions of the idiotypic sera with other LBMP. In these
systems the determinants identified (IdX) were common to the immunizing
protein and the "coated protein" but did not involve the IdI determinant. The
many cross-reacting sera in Table 11 suggested common IdX determinants were
prevalent among the LBMP. Thus, many of the antisera raised to different
LBMP might be identifying the same determinants. This made it possible to
construct a variety of HI systems (designated by the letters A to J) (Table IV) in
which an antiserum was reacted with a myeloma protein not involved in the
immunization . 12 different LBMP were used to inhibit each of the systems
described in Table IV and instead of finding the same pattern of inhibition we
found a variety of patterns of inhibition. This indicated that there were many
cross-specific idiotypic determinants among the LBMP. Based on the pattern of
inhibition using 10 IdX systems, 10 corresponding IdX determinants were
identified, designated A to J (Table IV). As may be seen some ofthe inhibitions
were judged to be only partial by the low titer ofinhibition shown by the LBMP
for a given IdX-HA system .
With three antisera, designated 10789, 10898, 10909, more thanone IdX system
was constructed. The anti-E109 antiserum 10898 identified two different
cross-specific determinants D and G. These two specificities were distinguished
by the A4 which inhibited Gbut not the D system and the strong inhibition of
A51 in the D system and its relative inability to inhibit the G system . Two
different IdX specificities E and F were identified by the anti-T803 antiserum
HA titers (log 2)
SRBC coated with myeloma proteins
Absorbed
A A A U W U J E Am T
4 47 48 61 3082 10 606 109 1 803
10559 Anti-A48 W3082 0 0 16 0 0 0 0 0 0 0
10548 Anti-A47 U61 0 19 0 0 0 0 0 0 0 0
10544 Anti-A4 U61 15 0 0 0 0 0 0 0 0 0
10570 Anti-U61 W3082 0 0 0 14 0 0 0 0 0 0
10789 Anti-W3082 U61 0 0 0 0 14 0 0 0 0 0
10898 Anti-E109 T803 0 0 0 0 0 0 0 11 0 0
10878 Anti-Aml T803 0 0 0 0 0 0 0 0 15 0
10909 Anti-T803 E109 0 0 0 0 0 0 0 0 0 13
9305 Anti-U10 A4 0 0 0 0 0 12 0 0 0 0
6470 Anti-J606 None 0 0 0 0 0 0 11 0 0 0LIEBERMAN, POTTER, HUMPHREY, JR., MUSHINSKI, AND VRANA
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10909. No LBMP was inhibitory in an HI-IdX system that was not directly
agglutinated in the corresponding HA system (Table II) .
Most of the IdX systems were highly sensitive to inhibition and the myeloma
protein inhibitors could inhibit completely at concentrations of 1 jug/ml or less.
One system J was relatively insensitive.
Idiotypic Individual Determinants of Anti-Aerobacter and Anti-Inulin An-
tibodies. The HI system was used to determine if the IdI identified by
specifically absorbed antisera described on Table III were shared by any of the 13
LBMP used in this study (Table V) . For this purpose each of the specific anti-Idl
antisera was reacted to the homologous protein-coated SRBC and then each of
the 13 levan proteins were used as inhibitors of this system . No shared IdI was
found and each of the 10 LBMP that were used to prepare antisera were shown to
have idiotypic individual determinants designated IdI-1 through IdI-10.
Levan IdX and Levan IdI not on 106 Nonlevan-Binding Myeloma Proteins.
106 nonlevan-binding myeloma proteins of various classes were tested for the
levan IdI and IdX determinants described in this paper (Table VI) . 68 IgA, 2 IgM,
11 IgG1, 9 IgG2a, 13 IgG2b, and 3 IgG3 myeloma proteins were included. Only one
myeloma protein (IgA, ABPC28) was found to have a shared determinant (IdI-3)
with a LBMP (A47) . No other Idl or IdX determinants were found among the 106
nonlevan-binding myeloma proteins.
Inhibition with /32-+1 Fructosan Trisaccharide.
￿
We attempted to determine
the relationship of the IdI and IdX determinants to the fructosan-binding site. To
do this, cells coated with LBMP were equilibrated with varying concentrations of
fructosan trisaccharide (the highest concentration was 0.028 M) and to these
anti-idiotypic antibody was added (Tables VII and VIII) . Six Idl systems were not
inhibited by 0.028 M trisaccharide: Idl 2, 3, 7, 8, and 9 (Table VII) and IdX I and
J and weakly B (Table VII) . Inhibition by the highest concentrations of inhibitor
was obtained with the IdI-6 and IdX-F systems. Inhibition with lower concentra-
tions of hapten was observed with all of the other Idl and IdX systems indicating
that the idiotypic determinants in question were close to if not actually part of
the antigen-binding site .
The two IdI systems 2 and 7 (individual specificities of U10 and A48 proteins)
and the IdX systems I and J (which identified cross specific determinants on A48
and on several inulin-binding proteins [see Table IV ], were not inhibited by
#2-.1 fructosan trisaccharide. A48 and U10 proteins do not bind 02-+1 fructosans
and hence it would not be expected that they would be inhibited by the
(32-.1-linked trisaccharide.
Discussion
In this study we have examined V-region-associated antigenic determinants of
13 LBMP which comprise the largest related group of antigen-binding myeloma
proteins thus far described. The LBMP in the BALB/c mouse were divided into
two groups: the anti-inulins (11 proteins) and the nonanti-inulin (2 proteins) or
the anti-A. levanicum levans. The first group is known to bind ,82---1-linked
fructosans (11) and the second group does not bind ,82--1-linked fructosans but isLIEBERMAN, POTTER, HUMPHREY, JR., MUSHINSKI, AND VRANA
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TABLE VI
Myeloma Proteins that do not Bind Levan Tested for Leu IdI and Leu IdX Determinants
*Levan IdI-3 found on AbPc 28 IgA myeloma protein.
hypothesized to bind fructosans with (32---6 linkages. The latter specificity is as
yet unproven.
The division of the Lvan-binding myelomas into two groups is further
supported by a limited amount of structural data on partial amino acid
sequences of the Vkappa and VHIII subgroups of five of the proteins. In the mouse
there are at least 25 subclasses of kappa and one of lambda based on the amino
terminal sequence to Cys23 (16, 26, 27). VH sequences have recently been divided
into four large groups and within each of these there is evidence to suggest still
further subdivisions (28) . Functionally related proteins with hapten-binding
activities of al-3 dextran (14, 15) al,6 dextran (14), and 06D galactan (17)
all fall into the same Vkappa and VH, subclasses based upon partial amino
terminal sequences through the Cys 23 peptide for 01_6D galactans and the
first Wu-Kabat hypervariable region for the al,3 dextrans. The myeloma
proteins W3082, J606 (27, 28), A4, and Aml (unpublished data of Vrana and
Rudikoff) fall into the same Vkappa and VHIII subclasses while the noninulin
Aerobacter Lvan-binding proteins (28) W5476 (P. Barstad, personal communica-
tion), and U10 (S . Rudikoff, unpublished data) fall into different Vkappa and VH,
subclasses. Thus, the antilevans are divided into two different hapten-binding
groups comprising different V,, and VH pairs that make up the binding sites.
A striking finding in the present experiments was the large number of different
Antiserum Antigen Idl
determinants
IgA
68
IgM
2
IgGI
11
IgG2a
9
IgG2b
13
IgG3
3
Anti-J606 J606 1 0 0 0 0 0 0
Anti-A48 A48 2 0 0 0 0 0 0
Anti-A47 A47 3 1* 0 0 0 0 0
Anti-U61 U61 4 0 0 0 0 0 0
Anti-W3082 W3082 5 0 0 0 0 0 0
Anti-A4 A4 6 0 0 0 0 0 0
Anti-U10 U10 7 0 0 0 0 0 0
Anti-E109 E109 8 0 0 0 0 0 0
Anti-Aml Aml 9 0 0 0 0 0 0
Anti-T803 T803 10 0 0 0 0 0 0
IdX
determinants
Anti-A4 U61 A 0 0 0 0 0 0
Anti-T803 W3082 B 0 0 0 0 0 0
Anti-E109 W3082 C 0 0 0 0 0 0
Anti-E109 Aml D 0 0 0 0 0 0
Anti-T803 E109 E 0 0 0 0 0 0
Anti-T803 Aml F 0 0 0 0 0 0
Anti-E109 A4 G 0 0 0 0 0 0
Anti-Aml A4 H 0 0 0 0 0 0
Anti-A48 A47 1 0 0 0 0 0 0
Anti-A47 A48 1 0 0 0 0 0 0LIEBERMAN, POTTER, HUMPHREY, JR., MUSHINSKI, AND VRANA
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TABLE VII
Inhibition of IdI Systems with B2 -. 1 Fructosan Trisaccharide (FTS)
NI = No inhibition at 0.028 M.
Inhibition of IdX Systems with B2 - 1 Fructosan Trisaccharide (FTS)
TABLE VIII
idiotypic determinants among the 11 inulin-binding myeloma proteins Table IX.
These proteins as mentioned are probably codedby V L and VH structural genesof
the same subgroup . Each of the proteins thus fartested in this group was found to
have its own specific Idl determinant and further each protein had two to nine
cross-specific determinants . These multiple antigenic differences reflected by the
presence of Idl determinants and dissimilarities in distribution of IdX determi-
nants appear to be due to a structural variation in different and discontinuous
portions of the Vkalp. andVH polypeptide chains. Some changes are relatedto the
antigen binding site region as demonstrated by the ability of the fructosan
hapten to inhibit the interaction of anti-idiotype antibody from binding the
idiotypic determinant, while others not inhibited by hapten were outside the
sites. Structural studies on the antigen-binding sites of the MOPC603 (29) and
New protein (30) have revealed that the binding site region is a continuous sur-
face formed by five or six loops or bends of beta-pleated sheets. These particular
segments of the V, and VH regions correspond to the Wu-Kabat hypervariable
Antiserum to
myeloma
protein
SRBC
coupled
with:
Antiserum
dilution
IdX system
FTS giving
complete inhibition
mol
10544 A4 U61 400 A 0.00175
10909 T803 W3082 800 B 0.028
10898 E109 W3082 500 C 0.00087
10898 E109 Aml 100 D 0.00087
10909 T803 E109 400 E 0.00043
10909 T803 Aml 100 F 0.00175
10898 E109 A4 500 G 0.00087
10878 Aml A4 100 H 0.00043
10559 A48 A47 800 I NI
10548 A47 A48 100 J NI
Antiserum to
myeloma protein
Dilution
(reciprocal)
Idl system
FTS giving
complete inhibition
mol
9302 U10 800 7 NI
10559 A48 100,000 2 NI
10878 Aml 50,000 9 NI
10898 E109 500 8 NI
10548 A47 50,000 3 NI
10544 A4 12,000 6 0.0035
10570 U61 12,000 4 0.00087
10789 W3082 50,000 5 0.00175
10909 T803 12,000 10 0.00175
6470 J606 100 1 NI116
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TABLE IX
Cross-Specific (IdX) System
IdX determinants
region (31) . Variations in different loops are probably responsible for the multiple
antigenic differences which would account for the observation that many of the
IdX determinants appear to vary independently of each other rather than
coordinately. For example, IdX determinants A and D may occur in the same
protein while in others only A or D are present and in still other proteins neither
of the two determinants was seen.
The most intriguing aspect of the idiotypes of the LBMP aside from their
multiplicity was the fact that most of them involved structures near the binding
site without apparently disturbing the ability to bind the antigen. Regardless of
what the biological mechanism of variation is, it apparently induces sequence
changes close to but not directly involved in antigen binding. The structural
variations responsible for the antigenic differences might be regarded as
permissive changesnot affecting thefunction of the molecules. It should be noted
that this includes not only the binding of the hapten but also includes
interactions of the myeloma proteins with the whole carrier polysaccharide.
The genetic basis for such diversity among functionally related proteins is not
resolved. It could be due to a cluster of closely related structural genes that have
duplicated and accumulated mutations but which have not yet diverged by
losing their ability to form molecules that bind #2,1 linked fructosans. Alterna-
tively, it could be argued the differences would have resulted from mutations
that have developed in somatic cells in single Vkappa and V,, structural genes. The
two mechanisms, multiple germ line genes and somatic mutations, are not
mutually exclusive and it is possible that the multiplicity of idiotypes in the
LBMP is due to a combination of both mechanisms .
It is of interest to note that the noninulin-binding protein A48 shared two IdX
determinants with proteins in the inulin-binding group. These determinants
were not inhibited by hapten. This similarity among proteins of different
subclasses may be due to a structural relationship between Vkappa or V,, genes.
Myeloma
protein Idl
Hapten
inhibition . . . . . . . .
A
+
B
+
C
+
D
+
E
+
F
+
G
+
H
+
I
-
J
U10 7 - - - - - - - - - -
A48 2 - - - - - - - - + +
A47 3 - - - - - - - - + +
J606 1 - - - t + t + - t
U61 4 + + r + + + + + + -
W3082 5 + + + + + + + - + +
T803 10 + + + + + + + - + -
E109 8 + - + + + - + - + +
Aml 9 - - + + t + + + + +
A4 6 + - + - t - + + t -
A51 - + - + + - - - + + -
M702 - + - + t - - + + + +LIEBERMAN, POTTER, HUMPHREY, JR., MUSHINSKI, AND VRANA
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Possibly in the mouse one of the genes evolved from the other, by duplication.
Alternatively, the antigenic similarity may simply be due to chance. Other
possibilities are that A48 may be completely different from any of the other
proteins by having different Vkappa or VH subunits or may have evolved from an
unusual pair of VL and VH units one of which is from the type involved in B2_l
fructosan-binding proteins while the other is in the B2,6 fructosan-binding
group.
Three other relevant systems of antigen-binding myeloma proteins have been
studied antigenically and structurally in the BALB/c mouse: the al,3 dextrans
(12, 13, 15), ,dl,6D galactans (17), and the T15-S63 group of phosphorylcholine-
binding proteins (7). In all three of these systems the specific binding function is
governed by specific pairs of VL and VH genes. IdI and IdX determinants have
been found in the al~3 dextran system and we have found IdI (17) and IdX
(unpublished observations) in the ,Q1,6D galactan system. The T15-S63 system
has proven to be unusual, inasmuch as all proteins in this group have the same
Idl determinant which also happens to be a genetic antigen (8). If a somatic
mutational process were in fact responsible for the variations it would be
expected that all V-region genes would be subject to change, which apparently is
not the case with the T15-S63 phosphorylcholine-binding proteins. This result
suggests that variations are determined at the germ line gene level and that
multiplicity of idiotypes reflects multiple genes. Very recently however some
evidence has been presented that there are a variety of normal phosphorylcho-
line-binding proteins in the mouse (32) . The selection of a predominant type in
both antibody and myeloma populations may be the result of factors that select
these clones preferentially.
Summary
13 levan-binding myeloma proteins (LBMP) of BALB/c origin were classified
into two groups with different binding specificities ; one group of 11 proteins
bound ,82-1 fructosans, a second group of two proteins bound fructosans
probably of 02,6 linkage. Anti-idiotypic sera prepared to 10 of the proteins in the
appropriate strains of mice identified numerous idiotypic determinants . Each
protein used for immunization had its own unique individual idiotypic specifici-
ties (IdI) and in addition most of the proteins carried two-nine cross-specific or
shared idiotypes (IdX) that were found only among LBMP, and notfound in 106
non-LBMP. Most of the IdX determinants and only four of the IdI determinants
of the #2,1 fructosan binding group were located in the antigen-binding site. The
multiplicity of antigenic differences in this functionally related group of
immunoglobulins reveals an unexpected degree of heterogeneity in V-regions that
appears to be unrelated to binding.
Received for publication 17 March 1975.
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